Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso

Rouamba, Toussaint; Ouédraogo, Espérance; Barry, Houreratou; Yaméogo, Nobila Valentin; Sondo, Apoline; Boly, R.; Zoungrana, Jacques; Ouédraogo, Abdoul Risgou; Tahita, Marc Christian; Poda, Armel; Diendéré, Arnaud Eric; Ouédraogo, M.; Valéa, Innocent; Traoré, Isidore; Tarnagda, Zékiba; Drabo, Maxime; Tinto, Halidou

doi:10.1016/j.ijid.2022.02.034

Cited by 4 publications

(2 citation statements)

References 30 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chloroquine has been withdrawn in Ghana and many other sub-Saharan African countries because of P. falciparum drug resistance to this antimalarial. A larger study coupled with molecular data would be needed in defining Chloroquine’s suitability for treating co-infections amid the current withdrawal from the clinics in Africa ( 20 , 21 ). Quinine, another old important antimalarial drug for almost 400 years, also potently inhibited P. ovale and P. falciparum fields isolates ( Fig.…”

Section: Discussionmentioning

confidence: 99%

Comparative Susceptibility of Plasmodium ovale and Plasmodium falciparum Field Isolates to Reference and Lead Candidate Antimalarial Drugs in Ghana

et al. 2023

View full text Add to dashboard Cite

Current malaria control and elimination tools such as drug treatments are not specifically targeting P.ovale . P. ovale can form hypnozoite and cause relapsing malaria. P. ovale is the third most dominant species in Africa and requires radical cure treatment given that it can form liver dormant forms called hypnozoites that escape all safe treatments. The inappropriate treatment of P. ovale would sustain its transmission in Africa where the medical need is the greatest.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Susceptibility of Plasmodium ovale and Plasmodium falciparum Field Isolates to Reference and Lead Candidate Antimalarial Drugs in Ghana

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Although HCQ has been shown to be well tolerated in COVID-19 patients in Burkina Faso, the drug could induce hemolytic crises in people with G6PD deficiency [19] [20] [21]. Despite the high prevalence of G6PDd in Burkina Faso, to our knowledge, no study determines the role of this genetic pathology in SARS-CoV-2 infection.…”

Section: Introductionmentioning

confidence: 99%

G6PD Deficiency and COVID-19 in Burkina Faso: A Possible Link?

Ouattara¹,

Traoré²,

Compaoré³

et al. 2023

JBM

View full text Add to dashboard Cite

Burkina Faso is a malaria-endemic country, with a high incidence of G6PD deficiency (G6PDd), which recorded its first case of COVID-19 in March 2020. G6PDd leads to a decrease in the efficiency of erythrocytes to combat oxidative stress, while SARS-CoV-2 infection induces massive production of Reactive Oxygen Species (ROS) in patients. In the present review, we discuss a possible link between G6PDd and SARS-CoV-2 infection. The mean prevalence of G6PDd in Burkina Faso is estimated at 16.6% among males and 6.5% among females. A total of 21,128 cases of COVID-19 have been recorded in Burkina Faso with 387 deaths reported (with a mortality rate of 1.15% among diagnosed cases) as of August 30, 2022. To our knowledge, no association study between G6PDd and SARS-CoV-2 infection has been conducted to date in Burkina Faso. However, several case reports around the world have described elevated risks of hemolysis and thrombosis, and other complications among G6PD-deficient patients infected with SARS-CoV-2. The use of Hydroxychloroquine (HCQ) has also been deemed unsafe by some authors for the treatment of COVID-19 among patients with G6PDd. Although HCQ has been shown to be well tolerated in COVID-19 patients in Burkina Faso, the drug could induce hemolytic crises in people with G6PD deficiency. G6PD is important in regulating ROS and maintaining erythrocyte homeostasis. In view of its high prevalence in Burkina Faso, determination of the G6PD status is required in COVID-19 patients for adequate management such as identifying a subset of COVID-19 patients for whom close monitoring and supportive care may be essential and to restrict treatment with HCQ.

show abstract